Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SLV026
MIFTS: 58

Salivary Gland Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Salivary Gland Carcinoma

About this section

MalaCards integrated aliases for Salivary Gland Carcinoma:

Name: Salivary Gland Carcinoma 12 15
Salivary Gland Cancer 12 36 54 42 15
Malignant Neoplasm of Salivary Gland 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Oral diseases Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:0050904 DOID:8850
KEGG 36 H01508
ICD9CM 34 142.8
SNOMED-CT 67 187648003
ICD10 32 C08
UMLS 71 C0153362
Sources

Summaries for Salivary Gland Carcinoma

About this section
KEGG : 36 Salivary gland carcinomas are rare tumours representing about 0.5% of all malignancies and less than 5 % of all head and neck cancers. These are a heterogeneous group of tumors that include 24 histologically distinct tumor types. Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor in adults and children. The most common genetic alteration in MECs is a unique translocation t(11;19)(q21;p13) producing the MECT1-MAML2 fusion protein. This fusion transcript can activate transcription of targets in the Notch pathway. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) overexpression is present in a minority of MECs and is associated with higher rate of metastasis and worse overall survival. Recent studies have evaluated the epidermal growth factor receptor family including EGFR and HER2 as potential therapeutic targets.

MalaCards based summary : Salivary Gland Carcinoma, also known as salivary gland cancer, is related to mucoepidermoid carcinoma and mammary analogue secretory carcinoma. An important gene associated with Salivary Gland Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Notch signaling pathway and ERK Signaling. The drugs Iodine and Doxepin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, lymph node and thyroid, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

MedlinePlus : 42 Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Salivary gland cancer is a type of head and neck cancer. It is rare. It may not cause any symptoms, or you could notice A lump in your ear, cheek, jaw, lip, or inside the mouth Fluid draining from your ear Trouble swallowing or opening the mouth widely Numbness, weakness, or pain in your face Doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. Treatment can include surgery, radiation therapy, and/or chemotherapy. NIH: National Cancer Institute

Sources

Related Diseases for Salivary Gland Carcinoma

About this section

Diseases in the Salivary Gland Carcinoma family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)
# Related Disease Score Top Affiliating Genes
1 mucoepidermoid carcinoma 32.3 SERPINA3 MAML2 EGFR CRTC1 CDKN2A
2 mammary analogue secretory carcinoma 32.0 ETV6 EGFR
3 adenoid cystic carcinoma 31.3 SERPINA3 MDM2 KIT EGFR CYLD CDKN2A
4 pleomorphic adenoma 31.0 MDM2 MAML2 CRTC1 CDKN2A
5 pleomorphic adenoma carcinoma 30.8 MAML2 CRTC1
6 oral cancer 30.6 MDM2 EGFR CDKN2A
7 small cell carcinoma 30.6 KIT EGFR CDKN2A
8 skin carcinoma 30.5 SOX2 MDM2 KIT H2AC18 EGFR CYLD
9 breast secretory carcinoma 30.5 SERPINA3 ETV6
10 adenocarcinoma 30.4 MET MDM2 KIT HGF FGFR1 EGFR
11 lung cancer susceptibility 3 30.4 MET HGF H2AC18 EGFR CDKN2A
12 basal cell carcinoma 30.3 SOX2 MDM2 KIT EGFR CYLD CDKN2A
13 leukemia, acute lymphoblastic 30.3 KIT H2AC18 FGFR1 ETV6 CDKN2A
14 breast cancer 29.6 SPHK1 SOX2 MET MDM2 KIT HGF
15 salivary gland cancer, adult 11.7
16 salivary gland mucinous adenocarcinoma 11.2
17 sublingual gland cancer 11.1
18 chronic erosive gastritis 10.6 MET HGF
19 mediastinum liposarcoma 10.5 MDM2 CDKN2A
20 malignant peritoneal mesothelioma 10.5 EGFR CDKN2A
21 doxorubicin induced cardiomyopathy 10.5 MET HGF EGFR
22 cervical adenoid cystic carcinoma 10.5 KIT CDKN2A
23 primary hypereosinophilic syndrome 10.5 FGFR1 ETV6
24 gastric liposarcoma 10.5 MDM2 KIT
25 esophagus verrucous carcinoma 10.5 MDM2 EGFR CDKN2A
26 verrucous carcinoma 10.5 MDM2 EGFR CDKN2A
27 laryngeal small cell carcinoma 10.5 KIT CDKN2A
28 maxillary sinus benign neoplasm 10.5 KIT CDKN2A
29 hypopharynx cancer 10.5 MET EGFR CDKN2A
30 acral lentiginous melanoma 10.5 MET KIT CDKN2A
31 vulvar disease 10.5 KIT EGFR CDKN2A
32 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.5 KIT FGFR1 ETV6
33 papillary squamous carcinoma 10.5 EGFR CDKN2A
34 synchronous bilateral breast carcinoma 10.5 KIT EGFR BRCA1
35 retroperitoneum carcinoma 10.5 MDM2 KIT CDKN2A
36 inflammatory liposarcoma 10.5 MDM2 CDKN2A
37 gliomatosis cerebri 10.5 MDM2 EGFR CDKN2A
38 peritoneal mesothelioma 10.5 MET EGFR CDKN2A
39 lip and oral cavity cancer 10.5 KIT EGFR CDKN2A
40 basaloid squamous cell carcinoma 10.5 SOX2 EGFR CDKN2A
41 lacrimal gland mucoepidermoid carcinoma 10.5 MAML2 CRTC1
42 deafness, autosomal recessive 97 10.5 SERPINA3 MET HGF
43 warthin tumor 10.5 MAML2 CRTC1
44 chronic eosinophilic leukemia 10.5 KIT FGFR1 ETV6
45 keratinizing squamous cell carcinoma 10.5 MAML2 EGFR CDKN2A
46 differentiated thyroid carcinoma 10.5 MET ETV6 EGFR
47 lung benign neoplasm 10.5 MET EGFR CDKN2A
48 breast malignant phyllodes tumor 10.5 SERPINA3 KIT EGFR
49 undifferentiated embryonal sarcoma of the liver 10.5 SERPINA3 MDM2
50 pancreas sarcoma 10.5 SERPINA3 MDM2 CDKN2A

Graphical network of the top 20 diseases related to Salivary Gland Carcinoma:



Diseases related to Salivary Gland Carcinoma
Sources

Symptoms & Phenotypes for Salivary Gland Carcinoma

About this section

GenomeRNAi Phenotypes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

26 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10 EGFR
2 Decreased viability GR00055-A-2 10 EGFR
3 Decreased viability GR00221-A-1 10 CDKN2A CYLD EGFR FGFR1 HGF KIT
4 Decreased viability GR00221-A-2 10 CYLD FGFR1 HGF
5 Decreased viability GR00221-A-3 10 CDKN2A
6 Decreased viability GR00221-A-4 10 CDKN2A EGFR HGF SOX2
7 Decreased viability GR00249-S 10 CYLD
8 Decreased viability GR00301-A 10 CYLD KIT
9 Decreased viability GR00386-A-1 10 FGFR1
10 Decreased viability GR00402-S-2 10 CYLD
11 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.78 FGFR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.78 MDM2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.78 EGFR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.78 FGFR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.78 MDM2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.78 BRCA1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.78 BRCA1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.78 MDM2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.78 MDM2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.78 BRCA1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.78 FGFR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.78 FGFR1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.78 BRCA1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.78 EGFR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.78 BRCA1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 EGFR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.78 MDM2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.78 FGFR1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.78 EGFR FGFR1 MDM2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.78 FGFR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.78 FGFR1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.78 MDM2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.78 H2AC18
34 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.78 FGFR1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 EGFR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.78 EGFR
37 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.78 H2AC18
38 Decreased substrate adherent cell growth GR00193-A-1 9.7 KIT MET
39 Decreased substrate adherent cell growth GR00193-A-2 9.7 KIT
40 Decreased substrate adherent cell growth GR00193-A-3 9.7 MET
41 Decreased substrate adherent cell growth GR00193-A-4 9.7 FGFR1 KIT MET

MGI Mouse Phenotypes related to Salivary Gland Carcinoma:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 ACTN4 BRCA1 CDKN2A EGFR ETV6 FGFR1
2 endocrine/exocrine gland MP:0005379 10.47 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
3 cellular MP:0005384 10.46 ACTN4 BRCA1 CDKN2A CYLD EGFR ETV6
4 growth/size/body region MP:0005378 10.46 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
5 homeostasis/metabolism MP:0005376 10.43 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
6 immune system MP:0005387 10.42 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
7 behavior/neurological MP:0005386 10.41 BRCA1 CDKN2A CRTC1 CYLD FGFR1 HGF
8 embryo MP:0005380 10.41 ACTN4 BRCA1 CDKN2A EGFR ETV6 FGFR1
9 hematopoietic system MP:0005397 10.41 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
10 digestive/alimentary MP:0005381 10.38 ACTN4 BRCA1 CDKN2A CYLD EGFR ETV6
11 mortality/aging MP:0010768 10.34 ACTN4 BRCA1 CDKN2A CYLD EGFR ETV6
12 integument MP:0010771 10.31 ACTN4 BRCA1 CDKN2A CYLD EGFR ETV6
13 nervous system MP:0003631 10.25 ACTN4 BRCA1 CDKN2A EGFR FGFR1 HGF
14 muscle MP:0005369 10.22 ACTN4 BRCA1 CDKN2A EGFR FGFR1 ISL1
15 craniofacial MP:0005382 10.21 ACTN4 EGFR FGFR1 ISL1 KIT MDM2
16 neoplasm MP:0002006 10.2 ACTN4 BRCA1 CDKN2A CYLD EGFR ETV6
17 liver/biliary system MP:0005370 10.16 ACTN4 CDKN2A EGFR ETV6 HGF KIT
18 limbs/digits/tail MP:0005371 10.13 BRCA1 CYLD EGFR FGFR1 ISL1 KIT
19 hearing/vestibular/ear MP:0005377 10.12 ACTN4 EGFR FGFR1 HGF ISL1 KIT
20 normal MP:0002873 10.11 BRCA1 CYLD EGFR ETV6 FGFR1 ISL1
21 no phenotypic analysis MP:0003012 10.1 CDKN2A EGFR ETV6 FGFR1 HGF ISL1
22 renal/urinary system MP:0005367 9.96 ACTN4 BRCA1 EGFR FGFR1 ISL1 KIT
23 pigmentation MP:0001186 9.87 BRCA1 CDKN2A EGFR HGF KIT MDM2
24 reproductive system MP:0005389 9.85 BRCA1 CDKN2A CRTC1 EGFR FGFR1 ISL1
25 respiratory system MP:0005388 9.56 ACTN4 BRCA1 CDKN2A CYLD EGFR KIT
26 skeleton MP:0005390 9.32 ACTN4 BRCA1 CDKN2A EGFR FGFR1 HGF
Sources

Drugs & Therapeutics for Salivary Gland Carcinoma

About this section

Drugs for Salivary Gland Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
3
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
4
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
5
Promethazine Approved, Investigational Phase 3 60-87-7 4927
6
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
7
Cadexomer iodine Experimental Phase 3 94820-09-4
8 Hypnotics and Sedatives Phase 3
9 Neurotransmitter Agents Phase 3
10 Antidepressive Agents Phase 3
11 Psychotropic Drugs Phase 3
12
Histamine Phosphate Phase 3 51-74-1 65513
13 Histamine Antagonists Phase 3
14 Antidepressive Agents, Tricyclic Phase 3
15 Muscarinic Agonists Phase 2, Phase 3
16 Cholinergic Agents Phase 2, Phase 3
17
Nintedanib Approved Phase 2 656247-17-5 56843413
18
Racepinephrine Approved Phase 2 329-65-7 838
19
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
20
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
21 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
22
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
23
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
24
Testosterone Approved, Investigational Phase 2 58-22-0 6013
25
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
26
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
27
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
28
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
29
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
30
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
31
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
32
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
33
Pembrolizumab Approved Phase 2 1374853-91-4
34
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
35
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
36
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
37
Adenosine Approved, Investigational Phase 2 58-61-7 60961
38
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
39
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
40
Bicalutamide Approved Phase 2 90357-06-5 56069 2375
41
Lenvatinib Approved, Investigational Phase 2 417716-92-8
42
Ipilimumab Approved Phase 2 477202-00-9
43
nivolumab Approved Phase 2 946414-94-4
44
Goserelin Approved Phase 2 65807-02-5 47725 5311128
45
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
46
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
47
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
48
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
49
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
50
Abiraterone acetate Phase 2 154229-18-2 57336518

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 A Randomized Control Trial (RCT) of Using Iodine-125 Brachytherapy Versus Intensity-modulated Radiation Therapy (IMRT) to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
2 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
3 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
4 Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study Unknown status NCT02558387 Phase 2 BIBF1120
5 Phase II Trial of Abiraterone Acetate in Patients With Relapsed and/or Metastatic, Castration Resistant Salivary Gland Cancers Unknown status NCT02867852 Phase 2 Abiraterone acetate
6 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
7 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
8 Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study Completed NCT01703455 Phase 2 Sorafenib
9 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
10 Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma Completed NCT02393820 Phase 2 pazopanib
11 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
12 A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
13 Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers Completed NCT01613768 Phase 2 eribulin mesylate
14 Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198) Completed NCT00509002 Phase 2 Gefitinib
15 Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract Completed NCT02857712 Phase 2 Axitinib
16 A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas Completed NCT00045669 Phase 2 imatinib mesylate
17 Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas Completed NCT00004163 Phase 2 Trastuzumab
18 Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study. Recruiting NCT03360890 Phase 2 Pembrolizumab;Docetaxel
19 A Multicenter Phase I/II Trial of A Novel MDM2 Inhibitor (APG-115) With or Without Platinum Chemotherapy in P53 Wild-Type Salivary Gland Carcinoma Recruiting NCT03781986 Phase 1, Phase 2 APG-115;Carboplatin
20 A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas Recruiting NCT04620187 Phase 2 Ado-trastuzumab (T) emtansine (T-DM1);Standard of Care Chemotherapy
21 Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111 Recruiting NCT03942653 Phase 2 Goserelin Acetate;Pembrolizumab
22 A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs) Recruiting NCT01969578 Phase 2 bicalutamide + triptorelin;Cisplatin + Doxorubicin;Carboplatin + Paclitaxel
23 Lutetium-177-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer, a Phase II Pilot Study. Recruiting NCT04291300 Phase 2 Lutetium-177-PSMA-I&T
24 A Phase II Study of Lenvatinib Plus Pembrolizumab in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Recruiting NCT04209660 Phase 2 Lenvatinib;Pembrolizumab
25 Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers Recruiting NCT03749460 Phase 1, Phase 2
26 The Efficacy of Cabozantinib in Advanced SAlivary Gland Cancer Patients, a Phase II Clinical Trial Active, not recruiting NCT03729297 Phase 2 Cabozantinib
27 Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland Active, not recruiting NCT03146650 Phase 2
28 A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck Active, not recruiting NCT03132038 Phase 2 Nivolumab
29 A Phase II Study of Nivolumab Plus Ipilimumab in Patients With Recurrent/Metastatic Salivary Cancers Active, not recruiting NCT03172624 Phase 2 Nivolumab;Ipilimumab
30 An Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Apalutamide in Combination With Gonadotropin-releasing Hormone (GnRH) Agonist in Subjects With Locally Advanced or Recurrent/Metastatic and Androgen Receptor (AR) Expressing Salivary Gland Carcinoma Active, not recruiting NCT04325828 Phase 2 Apalutamide;GnRH Agonist
31 Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma Terminated NCT00126607 Phase 2
32 Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Patients With Locally Advanced, Incurable, Salivary Gland Cancers Terminated NCT00101075 Phase 2 Capecitabine;Oxaliplatin
33 Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck. Active, not recruiting NCT01847326 Phase 1 carboplatin;paclitaxel albumin-stabilized nanoparticle formulation;fluorouracil;hydroxyurea
34 A Phase I Study Of PV701 In Patients With Head And Neck Squamous Cell Carcinoma Terminated NCT00081211 Phase 1
35 Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis Unknown status NCT02401763
36 Neurocognitive Functioning in Adults With Upper Aerodigestive System Cancers Completed NCT00533884
37 68Ga-PSMA-PET/CT Imaging for Locally Advanced, Recurrent and Metastatic Adenoid Cystic Carcinoma or Salivary Duct Carcinoma Completed NCT03319641
38 A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer Recruiting NCT02589938
39 Biomarkers and Dysplastic Respiratory Epithelium Recruiting NCT00900419
40 Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas Recruiting NCT03687294
41 Genomic Profiling and Matched Therapy for Recurrent or Metastatic Salivary Gland Neoplasms Recruiting NCT02069730 Selinexor;EGFR or HER2 Inhibitor;FGFR Inhibitor;C-KIT Inhibitor;Anti-androgen;NOTCH Inhibitor;MEK or PI3K Inhibitor
42 Effect of Androgen Deprivation Therapy on Uptake of PSMA Ligand in Patients With Salivary Duct Carcinoma: an Explorative Study. Recruiting NCT04214353
43 Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure Active, not recruiting NCT00530049
44 Electroacupuncture for Xerostomia in Head and Neck Patients Terminated NCT00623129

Search NIH Clinical Center for Salivary Gland Carcinoma

Sources

Genetic Tests for Salivary Gland Carcinoma

About this section
Sources

Anatomical Context for Salivary Gland Carcinoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Salivary Gland Carcinoma:

19
Salivary Gland

MalaCards organs/tissues related to Salivary Gland Carcinoma:

40
Salivary Gland, Lymph Node, Thyroid, Breast, Liver, Skin, Bone
Sources

Publications for Salivary Gland Carcinoma

About this section

Articles related to Salivary Gland Carcinoma:

(show top 50) (show all 701)
# Title Authors PMID Year
1
Diagnostic accuracy of ultrasound superb microvascular imaging for parotid tumors: A protocol for systematic review and meta-analysis. 42
33530166 2021
2
Individualized Use of Facelift, Retroauricular Hairline, and V-Shaped Incisions for Parotidectomy. 42
32949504 2020
3
Clinical and pathological analysis of 10 cases of salivary gland epithelial-myoepithelial carcinoma. 42
33031333 2020
4
CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. 61 54
19159612 2009
5
Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. 54 61
18355439 2008
6
Expression and cellular localization of TSC-22 in normal salivary glands and salivary gland tumors: implications for tumor cell differentiation. 54 61
18288391 2008
7
Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. 54 61
16469527 2006
8
CD151 forms a functional complex with c-Met in human salivary gland cancer cells. 61 54
16139245 2005
9
TSC-22 (TGF-beta stimulated clone-22): a novel molecular target for differentiation-inducing therapy in salivary gland cancer. 61 54
15379637 2004
10
Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma. 54 61
13679209 2003
11
Cytoplasmic TSC-22 (transforming growth factor-beta-stimulated clone-22) markedly enhances the radiation sensitivity of salivary gland cancer cells. 54 61
11944908 2002
12
Expression of peroxisome proliferator-activated receptor gamma and the growth inhibitory effect of its synthetic ligands in human salivary gland cancer cell lines. 61 54
11836575 2002
13
Leucine zipper structure of TSC-22 (TGF-beta stimulated clone-22) markedly inhibits the anchorage-independent growth of salivary gland cancer cells. 54 61
11836610 2002
14
In vivo enhancement of chemosensitivity of human salivary gland cancer cells by overexpression of TGF-beta stimulated clone-22. 61 54
10854535 2000
15
Over-expression of TSC-22 (TGF-beta stimulated clone-22) markedly enhances 5-fluorouracil-induced apoptosis in a human salivary gland cancer cell line. 61 54
10879745 2000
16
Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. 54 61
9458104 1998
17
Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell. 54 61
9459148 1998
18
Salivary Duct Carcinoma: An Aggressive Salivary Gland Carcinoma with Morphologic Variants, Newly Identified Molecular Characteristics, and Emerging Treatment Modalities. 61
33526216 2021
19
Epithelial-Myoepithelial Carcinoma. 61
33526226 2021
20
Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers. 61
33526219 2021
21
Incidence and survival of salivary gland cancer in children and young adults in Denmark: A nation-wide study for the period 1990-2015. 61
33550099 2021
22
Risk of second primary malignancy after minor salivary gland cancer: A Surveillance, Epidemiology, and End Results database analysis. 61
33590552 2021
23
Prognostic value of elective neck dissection in adenoid cystic carcinoma of head and neck: a meta-analysis. A call for randomized trials and international consensus. 61
33602647 2021
24
Prediction of Minor Salivary Gland Carcinoma: A Novel Nomogram and Risk Classification System for Overall Survival and Cancer-Specific Survival. 61
32692284 2021
25
Molecular detection of human papillomavirus-16 among Sudanese patients diagnosed with squamous cell carcinoma and salivary gland carcinoma. 61
33563329 2021
26
[Diagnosis and therapy of tumors with NTRK gene fusion]. 61
33258061 2021
27
The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay. 61
33498270 2021
28
Clinicopathological Factors are Predictors of Distant Metastases From Salivary Gland Carcinoma After Surgery Combined With 125I Internal Brachytherapy. 61
33581118 2021
29
The impact of nodal status in major salivary gland carcinoma: A multicenter experience and proposal of a novel N-classification. 61
33137587 2021
30
Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands. 61
33247629 2021
31
Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. 61
33467570 2021
32
Survival of salivary gland cancer stem cells requires mTOR signaling. 61
33479203 2021
33
Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies. 61
33148054 2021
34
The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma. 61
33481388 2021
35
Bilateral, buccinator myomucosal advancement flaps to reconstruct central upper labial myomucosal defects after ablation of early-stage cancer in minor salivary glands. 61
32463957 2021
36
Ambient ultraviolet radiation and major salivary gland cancer in the United States. 61
32246964 2020
37
Autophagy and salivary gland cancer: A putative target for salivary gland tumors. 61
33319639 2020
38
Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. 61
32736208 2020
39
QUAD shot: an effective cyclical hypofractionated palliative radiotherapy for salivary gland carcinoma. 61
33299577 2020
40
Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of AIRO-Head and Neck working group. 61
33320410 2020
41
Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy - Results from a large multicenter analysis. 61
33359662 2020
42
Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. 61
33169486 2020
43
Bilateral choroidal metastasis from adenoid cystic carcinoma of the submandibular salivary gland. 61
33198499 2020
44
Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma. 61
33039794 2020
45
Development of sentinel lymph node biopsy technique in patients with salivary gland cancer using the IDEAL framework. 61
32576478 2020
46
Salivary gland cancer in Southern Brazil: a prognostic study of 107 cases. 61
33247564 2020
47
Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment? 61
32744127 2020
48
mTOR Inhibition Ablates Cisplatin-Resistant Salivary Gland Cancer Stem Cells. 61
33073679 2020
49
A Case of 5-Fluorouracil-Induced Coronary Artery Vasospasm in a Patient With Salivary Gland Cancer. 61
33178539 2020
50
Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma. 61
33022760 2020
Sources

Variations for Salivary Gland Carcinoma

About this section

Cosmic variations for Salivary Gland Carcinoma:

9 (show top 50) (show all 451)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97921670 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 24
2 COSM135127924 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 24
3 COSM133255277 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.117A>C p.K39N 9:99129081-99129081 24
4 COSM97906020 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 24
5 COSM105721467 HRAS salivary gland,mouth floor,carcinoma,mucoepidermoid carcinoma c.35G>T p.G12V 11:534288-534288 24
6 COSM131674386 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 18
7 COSM143041461 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 18
8 COSM84855029 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 18
9 COSM110312003 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 18
10 COSM113659175 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 18
11 COSM99562983 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 18
12 COSM99625361 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 18
13 COSM86842324 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3854C>G p.T1285S 15:43422086-43422086 18
14 COSM88223810 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.501G>C p.Q167H 17:7675111-7675111 18
15 COSM93449405 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 18
16 COSM144019757 TP53 salivary gland,minor,carcinoma,NS c.742G>T p.D248Y 17:7674188-7674188 18
17 COSM106059381 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 18
18 COSM142685575 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.433G>C p.D145H 17:7675062-7675062 18
19 COSM105632589 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.523C>T p.R175C 17:7675089-7675089 18
20 COSM142828002 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.384G>C p.Q128H 17:7675111-7675111 18
21 COSM144319685 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.406C>T p.R136C 17:7675089-7675089 18
22 COSM111908814 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.483C>T p.A161= 17:7675129-7675129 18
23 COSM144039683 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.461A>T p.Q154L 17:7675118-7675118 18
24 COSM87905712 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 18
25 COSM122563517 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.173C>A p.P58H 17:7674962-7674962 18
26 COSM144178960 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.92C>A p.P31H 17:7674962-7674962 18
27 COSM143262651 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.73G>C p.D25H 17:7675062-7675062 18
28 COSM105627143 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 18
29 COSM144129656 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.184G>A p.E62K 17:7674870-7674870 18
30 COSM106065020 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.523C>T p.R175C 17:7675089-7675089 18
31 COSM144706904 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.544G>A p.E182K 17:7674870-7674870 18
32 COSM143946884 TP53 salivary gland,minor,carcinoma,NS c.*13-1G>A p.? 17:7670716-7670716 18
33 COSM144554314 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.452C>A p.P151H 17:7674962-7674962 18
34 COSM143374203 TP53 salivary gland,minor,carcinoma,NS c.*13-1G>A p.? 17:7670716-7670716 18
35 COSM144013113 TP53 salivary gland,minor,carcinoma,NS c.491G>A p.R164H 17:7675088-7675088 18
36 COSM93183307 TP53 salivary gland,minor,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 18
37 COSM93239617 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.661G>A p.E221K 17:7674870-7674870 18
38 COSM144109523 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.17A>T p.Q6L 17:7675118-7675118 18
39 COSM111765171 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 18
40 COSM112283179 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 18
41 COSM142842148 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 18
42 COSM88218639 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 18
43 COSM144182805 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.24G>C p.Q8H 17:7675111-7675111 18
44 COSM142858982 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 18
45 COSM145021213 TP53 salivary gland,minor,carcinoma,NS c.877-1G>A p.? 17:7670716-7670716 18
46 COSM144082461 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.6C>T p.A2= 17:7675129-7675129 18
47 COSM143166669 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.46C>T p.R16C 17:7675089-7675089 18
48 COSM144943249 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.452C>A p.P151H 17:7674962-7674962 18
49 COSM144091358 TP53 salivary gland,minor,carcinoma,NS c.298G>T p.D100Y 17:7674188-7674188 18
50 COSM142563012 TP53 salivary gland,minor,carcinoma,NS c.877-1G>A p.? 17:7670716-7670716 18
Sources

Expression for Salivary Gland Carcinoma

About this section
Search GEO for disease gene expression data for Salivary Gland Carcinoma.
Sources

Pathways for Salivary Gland Carcinoma

About this section

Pathways related to Salivary Gland Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Notch signaling pathway hsa04330

Pathways related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.72 SOX2 MET MDM2 KIT HGF FGFR1
2
GAB1 signalosome 65
Show member pathways
 13.05 MET MDM2 KIT HGF FGFR1 EGFR
3
Phospholipase-C Pathway 63
Show member pathways
 12.98 MET MDM2 KIT HGF FGFR1 EGFR
4
Endometrial cancer 36
Show member pathways
 12.81 MDM2 KIT FGFR1 EGFR CDKN2A
5
MAPK signaling pathway 36 1
12.68 MET KIT HGF FGFR1 EGFR
6
Ras signaling pathway 36
Show member pathways
 12.65 MET KIT HGF FGFR1 EGFR
7
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.55 MET MDM2 KIT HGF FGFR1 EGFR
8
Pathways in cancer 36
12.53 MET MDM2 KIT HGF FGFR1 EGFR
9
MicroRNAs in cancer 36
12.43 MET MDM2 EGFR CDKN2A BRCA1
10
PI3K-Akt signaling pathway 36
Show member pathways
 12.39 MET MDM2 MAML2 KIT HGF FGFR1
11
Apoptosis Pathway 70
Show member pathways
 12.37 MET MDM2 FGFR1 EGFR
12
Gastric cancer 36
Show member pathways
 12.37 MET KIT HGF FGFR1 EGFR CDKN2A
13
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.33 MET KIT HGF FGFR1 EGFR
14
Calcium signaling pathway 36
12.23 SPHK1 MET HGF FGFR1 EGFR
15
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.19 MET KIT HGF FGFR1 EGFR
16
Proteoglycans in cancer 36
12.11 MET MDM2 HGF FGFR1 EGFR
17
Tyrosine Kinases / Adaptors 4
12.04 MET KIT FGFR1 EGFR
18
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.95 SOX2 MET ISL1 HGF
19
Direct p53 effectors 1
11.93 MET MDM2 HGF EGFR
20
Listeria monocytogenes entry into host cells 65
Show member pathways
 11.79 MET HGF EGFR
21
Androgen receptor signaling pathway 1
11.79 MDM2 EGFR BRCA1
22
Glioma 36
Show member pathways
 11.77 MET MDM2 HGF FGFR1 EGFR CDKN2A
23
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.71 SOX2 ISL1 FGFR1
24
Platinum drug resistance 36
11.67 MDM2 CDKN2A BRCA1
25
Bladder cancer 36 1
11.66 MDM2 EGFR CDKN2A
26
Adherens junction 36
11.52 MET FGFR1 EGFR ACTN4
27
Cardiac Progenitor Differentiation 1
11.5 SOX2 KIT ISL1
28
Central carbon metabolism in cancer 36
11.47 MET KIT FGFR1 EGFR
29
FGF signaling pathway 1
11.44 MET HGF FGFR1
30
Signaling events mediated by TCPTP 1
Show member pathways
 11.38 MET HGF EGFR
31
Stabilization and expansion of the E-cadherin adherens junction 1
11.34 MET HGF EGFR
32
Arf6 signaling events 1
11.2 MET HGF EGFR
33
Extracellular vesicle-mediated signaling in recipient cells 1
11.13 MET HGF EGFR
34
G-protein signaling_Rap2B regulation pathway 23
10.96 MET KIT HGF FGFR1 EGFR
Sources

GO Terms for Salivary Gland Carcinoma

About this section

Cellular components related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.83 TSC22D1 SPHK1 SOX2 SERPINA3 MDM2 MAML2
2 receptor complex GO:0043235 9.56 MET KIT FGFR1 EGFR
3 platelet alpha granule lumen GO:0031093 9.33 SERPINA3 HGF ACTN4
4 nuclear body GO:0016604 9.02 MDM2 CRTC1 CDKN2A BRCA1 ACTN4

Biological processes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 10 SPHK1 MET KIT FGFR1 EGFR CDKN2A
2 positive regulation of cell proliferation GO:0008284 9.88 SPHK1 MDM2 KIT ISL1 FGFR1 EGFR
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.79 KIT HGF FGFR1
4 positive regulation of angiogenesis GO:0045766 9.78 SPHK1 ISL1 HGF BRCA1
5 liver development GO:0001889 9.77 MET HGF EGFR
6 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.73 SPHK1 EGFR ACTN4
7 peptidyl-tyrosine phosphorylation GO:0018108 9.73 MET KIT FGFR1 EGFR
8 cellular response to growth factor stimulus GO:0071363 9.72 SPHK1 MDM2 EGFR
9 MAPK cascade GO:0000165 9.72 MET KIT HGF FGFR1 EGFR
10 positive regulation of MAP kinase activity GO:0043406 9.71 KIT FGFR1 EGFR
11 positive regulation of cell differentiation GO:0045597 9.67 SOX2 ISL1 FGFR1
12 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.67 MET KIT FGFR1 EGFR
13 positive regulation of cell migration GO:0030335 9.65 SPHK1 KIT HGF EGFR ACTN4
14 epithelial cell proliferation GO:0050673 9.61 KIT HGF
15 positive regulation of phospholipase C activity GO:0010863 9.61 KIT FGFR1
16 amyloid fibril formation GO:1990000 9.59 MDM2 CDKN2A
17 hepatocyte growth factor receptor signaling pathway GO:0048012 9.58 MET HGF
18 tongue development GO:0043586 9.58 KIT EGFR
19 somatic stem cell division GO:0048103 9.57 KIT CDKN2A
20 chordate embryonic development GO:0043009 9.51 FGFR1 BRCA1
21 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.46 MET HGF
22 positive regulation of kinase activity GO:0033674 9.46 MET KIT FGFR1 EGFR
23 positive regulation of transcription by RNA polymerase II GO:0045944 9.36 SOX2 MET MDM2 MAML2 ISL1 HGF
24 positive regulation of protein kinase B signaling GO:0051897 9.35 MET KIT HGF FGFR1 EGFR

Molecular functions related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.92 TST SPHK1 MET MDM2 KIT FGFR1
2 kinase activity GO:0016301 9.63 SPHK1 MET KIT FGFR1 EGFR CDKN2A
3 5S rRNA binding GO:0008097 9.26 TST MDM2
4 protein tyrosine kinase activity GO:0004713 9.26 MET KIT FGFR1 EGFR
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 MET KIT FGFR1 EGFR
Sources

Sources for Salivary Gland Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....